Therapeutic monitoring of voriconazole in children less than three years of age: A case report and summary of voriconazole concentrations for ten children

Pediatric Infectious Disease Journal

Volumn 31, Issue 6, 2012, Pages 632-635

  Doby, Elizabeth H ^a   Benjamin Jr , Daniel K ^b   Blaschke, Anne J ^a   Ward, Robert M ^a   Pavia, Andrew T ^a   Martin, Paul L ^b   Driscoll, Timothy A ^b   Cohen Wolkowiez, Michael ^b   Moran, Cassandra ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Invasive aspergillosis; Pediatric; Pharmacokinetic; Therapeutic drug monitoring; Voriconazole

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMPHOTERICIN B LIPID COMPLEX; AMPICILLIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN GLUCURONIDE; CASPOFUNGIN; CEFOTAXIME; FLUCONAZOLE; GAMMA GLUTAMYLTRANSFERASE; GENTAMICIN; HYDROCORTISONE; INTRALIPID; MEROPENEM; MICAFUNGIN; PHENOBARBITAL; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; VORICONAZOLE;

ADRENAL INSUFFICIENCY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLUS FUMIGATUS; BILIRUBIN BLOOD LEVEL; BIRTH WEIGHT; CHILD; CLINICAL ARTICLE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MONITORING; ECHOGRAPHY; EPITHELIZATION; FOLLOW UP; FUNGUS ISOLATION; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENERAL CONDITION DETERIORATION; GESTATIONAL AGE; GRAFT VERSUS HOST REACTION; HIGH FREQUENCY OSCILLATION; HIGH FREQUENCY VENTILATION; HUMAN; ILEOSTOMY; INFANT; INVASIVE ASPERGILLOSIS; LAPAROTOMY; LIVER FUNCTION; MALE; NECROTIZING ENTEROCOLITIS; NEWBORN; NEWBORN SEPSIS; PREMATURITY; PRIORITY JOURNAL; SCHOOL CHILD; SOFT TISSUE DEFECT; STEADY STATE; TOTAL PARENTERAL NUTRITION; TREATMENT DURATION;

ANTIFUNGAL AGENTS; CHILD, PRESCHOOL; DRUG MONITORING; FEMALE; HUMANS; INFANT; INVASIVE PULMONARY ASPERGILLOSIS; MALE; PLASMA; PYRIMIDINES; TRIAZOLES;

EID: 84863393724     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31824acc33     Document Type: Article

References (24)

1. Walsh TJ, Anaissie EJ, Denning DW, et al.; Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46: 327-360.
2. Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single-or multiple-dose administration. Antimicrob Agents Chemother. 2004;48:2166-2172.
3. Neely M, Rushing T, Kovacs A, et al. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis. 2010;50:27-36.
4. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201-211.
5. Ueda K, Nannya Y, Kumano K, et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol. 2009;89:592-599.
6. Zonios DI, Gea-Banacloche J, Childs R, et al. Hallucinations during voriconazole therapy. Clin Infect Dis. 2008;47:e7-e10.
7. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481-504.
8. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45:649-663.
9. Pfizer Inc. Vfend U.S. physician prescribing information. New York, NY: Pfizer Inc.;revised 2011.
10. Walsh TJ, Driscoll T, Milligan PA, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother. 2010;54:4116-4123.
11. Burgos A, Zaoutis TE, Dvorak CC, et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics. 2008;121:e1286-e1294.
12. Spriet I, Cosaert K, Renard M, et al. Voriconazole plasma levels in children are highly variable. Eur J Clin Microbiol Infect Dis. 2011;30:283-287.
13. Shima H, Miharu M, Osumi T, et al. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age. Pediatr Blood Cancer. 2010;54:1050-1052.
14. Gerin M, Mahlaoui N, Elie C, et al. Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency. Ther Drug Monit. 2011;33:464-466.
15. Brüggemann RJ, van der Linden JW, Verweij PE, et al. Impact of therapeutic drug monitoring of voriconazole in a pediatric population. Pediatr Infect Dis J. 2011;30:533-534.
16. Frankenbusch K, Eifinger F, Kribs A, et al. Severe primary cutaneous aspergillosis refractory to amphotericin B and the successful treatment with systemic voriconazole in two premature infants with extremely low birth weight. J Perinatol. 2006;26:511-514.
17. Maples HD, Stowe CD, Saccente SL, et al. Voriconazole serum concentrations in an infant treated for Trichosporon beigelii infection. Pediatr Infect Dis J. 2003;22:1022-1024.
18. Muldrew KM, Maples HD, Stowe CD, et al. Intravenous voriconazole therapy in a preterm infant. Pharmacotherapy. 2005;25:893-898.
19. Santos RP, Sánchez PJ, Mejias A, et al. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. Pediatr Infect Dis J. 2007;26:364-366.
20. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J. 2002;21:240-248.
21. Ward RM, Tammara B, Sullivan SE, et al. Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). Eur J Clin Pharmacol. 2010;66:555-561.
22. Yanni SB, Annaert PP, Augustijns P, et al. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. Drug Metab Dispos. 2010;38:25-31.
23. Kassir N, Théorêt Y, Litalien C, et al. Population pharmacokinetics of intravenous and oral voriconazole in children. In: 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-14, 2009. Washington, DC: American Society for Microbiology; 2009. Abstract A1-586/40.
24. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36:630-637.COMMENTARY: Pediatric Antifungal Drug Development